6.1 Prescription Evaluation

6.1 Prescription Evaluation

Quick Answer: Before you label a medicine, evaluate the prescription as a legal and clinical instrument. Confirm who prescribed, for whom, what (drug, strength, form), how much, how to take it, when it was written, and that authentication (signature or electronic equivalent) is valid. Add Schedule 8 (S8) extra checks when needed, detect alterations, decide PBS versus private, and manage owing/partial supply without breaking remaining quantity or claim rules. If critical elements are missing or unsafe, clarify with the prescriber or withhold supply.

Dispensing under National Competency Standard 3.2.3 is not a packing task. It is a professional process that starts with prescription evaluation: is this document (or electronic token) complete, authentic, current, and capable of supporting a safe supply decision?

Why evaluation comes before everything else

A medicine can only be supplied lawfully when the authority to supply is established. In Australian practice that authority is usually a valid prescription (or another lawful authorisation recognised by schedule and jurisdiction). Clinical review, labelling, counselling, and PBS claiming all sit after you know the prescription is fit to act on.

Common exam and practice failures at this step include:

• Dispensing from incomplete or ambiguous directions
• Ignoring missing strength, form, or quantity
• Treating a PBS claim problem as if it fixed a legal defect
• Supplying S8 medicines on prescriptions that lack required extra particulars
• Accepting visibly altered paper scripts without investigation
• Confusing “patient wants it today” with “supply is lawful”

Legal completeness — the core particulars

Exact statutory wording differs between states and territories and between paper and electronic prescriptions. For the Intern Written Examination, master national principles: every prescription must identify the who, what, how much, how, and when with enough clarity for safe, auditable supply.

If a critical element is missing, illegible, or contradictory, do not invent the missing piece. Contact the prescriber for clarification, or refuse supply until remedied. Non-critical ambiguities that do not affect identity of medicine, dose safety, or legality may sometimes be resolved with patient confirmation and documentation — but never invent strength, form, or S8 particulars.

Patient and prescriber identity

Confirm the patient matches the person presenting (or the carer/agent with appropriate authority). Watch for similar names, outdated details, and hospital discharge scripts that may not match community records. For the prescriber, confirm they appear to be a recognised authorised prescriber for that medicine class in context (for example, some restricted medicines require specialist initiation or permit arrangements under state law). When in doubt, verify before supply.

Drug, strength, form, dose, quantity

Treat these as a package:

1. Drug — Is the medicine clearly specified? Abbreviations and look-alike names are high risk.
2. Strength — Multi-strength products (e.g. many opioids, anticoagulants, paediatric liquids) demand precision.
3. Form — Incorrect form can change bioavailability and legal schedule context (e.g. different products).
4. Dose — Directions must support safe use; unclear frequency or titration needs clarification.
5. Quantity — Must be consistent with directions, PBS maximum quantities (if PBS), and clinical duration cues.

A classic exam trap is a script that is “almost complete” but omits strength for a multi-strength S4, or quantity for an S8. Almost complete is not complete.

Electronic versus paper prescriptions

Australia’s electronic prescription framework uses tokens and conformant systems rather than a handwritten signature on paper. Principles for exam thinking:

Key point: Moving from paper to electronic changes how authenticity and remaining quantity are managed; it does not remove the pharmacist’s duty to evaluate clinical appropriateness, counselling needs, S8 controls, or PBS versus private pathway correctness.

When an electronic token cannot be retrieved, is already fully dispensed, or data appear incomplete, treat that as a block to supply until resolved through the correct electronic or prescriber pathway — not by improvising a paper substitute without lawful basis.

Schedule 8 extra particulars — principles

S8 controlled drugs attract stricter prescription requirements because of dependence, misuse, and diversion risk. Exact extra fields and wording vary by jurisdiction, but exam-ready principles include:

• Heightened identification of patient and prescriber details (often more complete name/address-type particulars than a simple S4)
• Unambiguous medicine, form, strength, quantity, and directions
• Date and authentication that meet controlled-drug rules
• Limits on what can be altered after writing; many changes require a new prescription or formal amendment pathway
• Integration with real-time prescription monitoring where applicable (state systems)
• Safe custody and recording obligations after the clinical decision to supply

PBS listing of an S8 does not soften S8 prescription law. Private S8 supply still requires S8-compliant authority to supply. If S8 particulars are incomplete, do not supply on “we’ll fix the paperwork later” pressure.

Detecting alterations and authenticity concerns

Pharmacists are expected to exercise reasonable diligence against forgery and unauthorised alteration.

Paper red flags (non-exhaustive):

• Different handwriting or ink for critical fields (quantity, drug name, patient name)
• Erasures, overwriting, or obvious additions after signature
• Unusually large quantities or out-of-character doses for the stated indication context
• Photocopy quality, missing security features where expected, or generic “clinic” details that cannot be verified
• Patient urgency combined with reluctance to allow verification

Electronic / process red flags:

• Token handling inconsistencies, duplicate presentation attempts, mismatched patient identity
• Pressure to override system warnings without clinical or technical resolution
• Requests to “just type it in” without a valid electronic or paper authority

Response pathway: pause supply, verify with the prescriber or system, document concerns, and refuse if authenticity cannot be established. Patient distress does not convert a forged or altered prescription into a legal one.

Owing and partial supply concepts

Real pharmacies often cannot supply the full prescribed quantity immediately (stock shortage, pack size mismatch, staged supply for safety).

Principles:

1. Partial supply — supply less than the full quantity now when clinically and legally appropriate, with a clear plan for the remainder.
2. Owing — document and track the balance still due so the patient receives remaining medicine without creating a second full claim or double-supply error.
3. Remaining quantity integrity — electronic systems and paper annotations must accurately reflect what has been supplied and what remains.
4. Clinical safety — partial supply is not a reason to skip counselling or monitoring alerts (e.g. opioids, antibiotics, anticoagulants).
5. Patient communication — explain what was supplied, when the balance should be available, and any interim risk (running out of essential medicine).

Never “complete” an owing by inventing a new prescription. Never claim PBS for a full quantity when only a partial quantity was supplied. Align stock movement, label quantity, counselling, and claim with the actual supply event.

PBS versus private — evaluate the pathway

Prescription evaluation includes deciding the funding pathway, which is separate from schedule legality.

Important distinctions:

• A prescription may be legally valid for private S4/S8 supply even if it does not meet a particular PBS authority rule — but then it is not claimable as that PBS item.
• Conversely, a PBS claim cannot legitimise a schedule-invalid or incomplete prescription.
• Visitors, overseas patients, or non-eligible people may still receive private supply of prescription medicines when the prescription and schedule rules are met.
• Authority Required items (including STREAMLINED codes) need compliant authority information for PBS supply; absence of authority does not automatically create private legality if the underlying prescription is defective for other reasons.

Practical evaluation workflow (exam model)

1. Authenticate — paper integrity or electronic token/system validity
2. Identify — patient and authorised prescriber
3. Complete particulars — drug, strength, form, dose, quantity, date, authentication, repeats
4. Schedule overlay — S4 vs S8 (and monitored medicines) extra requirements
5. Pathway — PBS (with authority rules if relevant) vs private
6. Supply logistics — full, partial, or owing with accurate remaining quantity
7. Escalate — clarify, amend, or withhold when any critical step fails

Only after this evaluation should you move into clinical appropriateness checks (Section 6.2), labelling (Section 6.3), and prescriber communication (Section 6.4).

Exam mindset

Intern Written items often present a script that looks routine until one element fails: missing strength, expired date, S8 particulars incomplete, electronic token already used, PBS authority absent, or a suspected alteration. Choose the action that protects legality and patient safety — clarify or withhold — rather than the option that prioritises speed or customer satisfaction alone.